RecruitingNot ApplicableNCT07209202

Fructose Intestinal Gluconeogenesis

Fructose Metabolism Effects on the Liver: Unraveling the Role of Defective Intestinal GNG in Individuals With Obesity


Sponsor

Touro University, California

Enrollment

40 participants

Start Date

Mar 2, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.


Eligibility

Min Age: 20 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This study investigates whether the small intestine plays a protective role when people consume fructose (a sugar found in fruit and many processed foods) by converting it to glucose before it reaches the liver, and whether this protective mechanism is impaired in people with obesity. Participants undergo a specialized metabolic test in which they consume meals with different levels of fructose while receiving stable isotope tracers to track how the body processes the sugar. Eligible participants are either lean adults (BMI 19–25) or obese adults (BMI 30–38) who do not have diabetes, liver disease, or certain metabolic conditions. The study involves four outpatient visits approximately 3 weeks apart, each including an overnight fast, a 6-hour fed metabolic study, and frequent blood and urine sample collections. This summary was prepared to help patients understand the study in plain language.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERHigh fructose meal

Liquid meals containing 55% total carbohydrate (16% fructose), 30% fat, 15% protein.

OTHERLow fructose meal

55% total carbohydrate (6% fructose), 30% fat, 15% protein.

OTHER13C labeled fructose, oral

Tracer amount of 13C labeled fructose administered orally in the meals.

OTHER13C labeled fructose, intravenous

Tracer amount of 13C fructose administered intravenously


Locations(1)

Touro University California

Vallejo, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07209202


Related Trials